

Sabina Signoretti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4789648/publications.pdf>

Version: 2024-02-01

258
papers

32,226
citations

4942

84
h-index

4535

171
g-index

265
all docs

265
docs citations

265
times ranked

41652
citing authors

#	ARTICLE	IF	CITATIONS
1	The landscape of somatic copy-number alteration across human cancers. <i>Nature</i> , 2010, 463, 899-905.	13.7	3,331
2	Renal cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17009.	18.1	1,727
3	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 135-145.	13.9	1,040
4	High-throughput oncogene mutation profiling in human cancer. <i>Nature Genetics</i> , 2007, 39, 347-351.	9.4	927
5	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. <i>Science</i> , 2018, 359, 801-806.	6.0	898
6	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015, 5, 1164-1177.	7.7	821
7	Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion. <i>Cancer Research</i> , 2005, 65, 3044-3048.	0.4	750
8	The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma. <i>Cancer Cell</i> , 2014, 26, 319-330.	7.7	665
9	Essential roles of PI(3)K-p110 ^{Î²} in cell growth, metabolism and tumorigenesis. <i>Nature</i> , 2008, 454, 776-779.	13.7	654
10	p63 Is a Prostate Basal Cell Marker and Is Required for Prostate Development. <i>American Journal of Pathology</i> , 2000, 157, 1769-1775.	1.9	538
11	Forkhead Transcription Factors Are Critical Effectors of Cell Death and Cell Cycle Arrest Downstream of PTEN. <i>Molecular and Cellular Biology</i> , 2000, 20, 8969-8982.	1.1	530
12	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , 2018, 23, 313-326.e5.	2.9	523
13	Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma. <i>Cancer Discovery</i> , 2014, 4, 1140-1153.	7.7	506
14	A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. <i>Nature Communications</i> , 2019, 10, 1617.	5.8	499
15	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. <i>Nature Medicine</i> , 2020, 26, 909-918.	15.2	488
16	SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. <i>Nature</i> , 2011, 470, 269-273.	13.7	462
17	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nature Genetics</i> , 2018, 50, 1271-1281.	9.4	438
18	Targeting Lactate Dehydrogenase-A Inhibits Tumorigenesis and Tumor Progression in Mouse Models of Lung Cancer and Impacts Tumor-Initiating Cells. <i>Cell Metabolism</i> , 2014, 19, 795-809.	7.2	411

#	ARTICLE	IF	CITATIONS
19	Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 3714-3721.	3.2	401
20	Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. <i>Nature</i> , 2002, 419, 162-167.	13.7	390
21	Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney. <i>Cancer Research</i> , 2009, 69, 4674-4681.	0.4	370
22	Genetic and Functional Studies Implicate <i>HIF1α</i> as a 14q Kidney Cancer Suppressor Gene. <i>Cancer Discovery</i> , 2011, 1, 222-235.	7.7	347
23	On-target efficacy of a HIF-2 α antagonist in preclinical kidney cancer models. <i>Nature</i> , 2016, 539, 107-111.	13.7	341
24	Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 519-532.	3.0	328
25	The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. <i>Cancer Cell</i> , 2004, 5, 253-261.	7.7	304
26	Landscape of tumor-infiltrating T cell repertoire of human cancers. <i>Nature Genetics</i> , 2016, 48, 725-732.	9.4	288
27	The Requirement for Cyclin D Function in Tumor Maintenance. <i>Cancer Cell</i> , 2012, 22, 438-451.	7.7	284
28	Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate. <i>Science</i> , 2019, 363, 1217-1222.	6.0	281
29	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. <i>Nature Genetics</i> , 2011, 43, 964-968.	9.4	270
30	Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib. <i>Cancer Discovery</i> , 2014, 4, 546-553.	7.7	266
31	Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 649-661.e5.	7.7	263
32	Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. <i>Oncotarget</i> , 2016, 7, 34341-34355.	0.8	258
33	Primary Cutaneous Marginal Zone B-Cell Lymphoma: A Recently Described Entity of Low-Grade Malignant Cutaneous B-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 1997, 21, 1307-1315.	2.1	249
34	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2015, 3, 1158-1164.	1.6	237
35	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 632-648.e8.	7.7	230
36	Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates. <i>Journal of Clinical Oncology</i> , 2014, 32, 1889-1894.	0.8	229

#	ARTICLE	IF	CITATIONS
37	An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. <i>Nature Genetics</i> , 2018, 50, 206-218.	9.4	229
38	Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial. <i>Clinical Cancer Research</i> , 2015, 21, 1071-1077.	3.2	217
39	VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. <i>Nature Cell Biology</i> , 2008, 10, 361-369.	4.6	216
40	LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 626-635.	1.9	208
41	Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. <i>Cancer Research</i> , 2013, 73, 2718-2736.	0.4	203
42	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 2445-2452.	3.2	193
43	BCR/ABL Regulates Expression of the Cyclin-dependent Kinase Inhibitor p27Kip1 through the Phosphatidylinositol 3-Kinase/AKT Pathway. <i>Journal of Biological Chemistry</i> , 2000, 275, 39223-39230.	1.6	188
44	Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine. <i>Cell</i> , 2016, 166, 126-139.	13.5	187
45	Role of the Cdc25A phosphatase in human breast cancer. <i>Journal of Clinical Investigation</i> , 2000, 106, 753-761.	3.9	186
46	p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 8105-8110.	3.3	185
47	The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2010, 16, 3628-3638.	3.2	180
48	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. <i>Journal of Clinical Oncology</i> , 2016, 34, 3655-3663.	0.8	174
49	Depletion of a Putatively Druggable Class of Phosphatidylinositol Kinases Inhibits Growth of p53-Null Tumors. <i>Cell</i> , 2013, 155, 844-857.	13.5	173
50	Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells. <i>Cancer Research</i> , 2004, 64, 8867-8875.	0.4	170
51	Potential Histologic and Molecular Predictors of Response to Temsirolimus in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 379-385.	0.9	168
52	A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. <i>EMBO Molecular Medicine</i> , 2014, 6, 519-538.	3.3	168
53	pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. <i>Science</i> , 2016, 353, 929-932.	6.0	165
54	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 78-86.	3.2	154

#	ARTICLE	IF	CITATIONS
55	A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression. <i>Cancer Cell</i> , 2008, 14, 146-155.	7.7	153
56	Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking <i>Rb1</i> or <i>Men1</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 13379-13386.	3.3	143
57	Identification of Luminal Breast Cancers That Establish a Tumor-Supportive Macroenvironment Defined by Proangiogenic Platelets and Bone Marrow-Derived Cells. <i>Cancer Discovery</i> , 2012, 2, 1150-1165.	7.7	142
58	Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. <i>Journal of Clinical Investigation</i> , 2002, 110, 633-641.	3.9	142
59	Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy. <i>Circulation</i> , 2010, 122, 1004-1016.	1.6	139
60	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. <i>Nature Communications</i> , 2019, 10, 4346.	5.8	139
61	A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. <i>Nature Genetics</i> , 2013, 45, 747-755.	9.4	138
62	Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. <i>Nature Medicine</i> , 2018, 24, 165-175.	15.2	137
63	SQSTM1 Is a Pathogenic Target of 5q Copy Number Gains in Kidney Cancer. <i>Cancer Cell</i> , 2013, 24, 738-750.	7.7	135
64	p63 regulates commitment to the prostate cell lineage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 11355-11360.	3.3	134
65	Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. <i>Nature Genetics</i> , 2013, 45, 739-746.	9.4	134
66	The High-Dose Aldesleukin Select-Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 561-568.	3.2	133
67	FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis. <i>Cancer Cell</i> , 2010, 18, 472-484.	7.7	127
68	A Working Group Classification of Focal Prostate Atrophy Lesions. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1281-1291.	2.1	123
69	Reciprocal Effects of STAT5 and STAT3 in Breast Cancer. <i>Molecular Cancer Research</i> , 2009, 7, 966-976.	1.5	121
70	Cells Lacking the <i>Rb1</i> Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. <i>Cancer Discovery</i> , 2019, 9, 230-247.	7.7	119
71	Diagnostic Utility of Immunohistochemical Staining for p63, a Sensitive Marker of Prostatic Basal Cells. <i>Modern Pathology</i> , 2002, 15, 1302-1308.	2.9	116
72	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. <i>Cancer Immunology Research</i> , 2015, 3, 1308-1315.	1.6	114

#	ARTICLE	IF	CITATIONS
73	Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. <i>Cancer Discovery</i> , 2017, 7, 750-765.	7.7	112
74	Does Arterial Spin-labeling MR Imagingâ€measured Tumor Perfusion Correlate with Renal Cell Cancer Response to Antiangiogenic Therapy in a Mouse Model?. <i>Radiology</i> , 2009, 251, 731-742.	3.6	111
75	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. <i>Journal of Clinical Oncology</i> , 2020, 38, 63-70.	0.8	109
76	Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2017, 72, 557-564.	0.9	108
77	Efficacy of Savolitinib vs Sunitinib in Patients With <i>MET</i> -Driven Papillary Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 1247.	3.4	105
78	Stabilization of β -catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. <i>Oncogene</i> , 2002, 21, 4099-4107.	2.6	102
79	Intermediate basal cells of the prostate: In vitro and in vivo characterization. <i>Prostate</i> , 2003, 55, 206-218.	1.2	97
80	Carbonic Anhydrase IX Expression in Renal Neoplasms. <i>American Journal of Clinical Pathology</i> , 2010, 134, 873-879.	0.4	97
81	Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. <i>Cancer Research</i> , 2002, 62, 89-98.	0.4	97
82	BRAF Mutations in Metanephric Adenoma of the Kidney. <i>European Urology</i> , 2012, 62, 917-922.	0.9	95
83	Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development. <i>PLoS Genetics</i> , 2016, 12, e1006242.	1.5	93
84	The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 758s-763s.	3.2	91
85	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Nonâ€Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018, 6, 758-765.	1.6	89
86	Vulnerabilities of <i>PTEN</i> â€ <i>TP53</i> -Deficient Prostate Cancers to Compound PARPâ€PI3K Inhibition. <i>Cancer Discovery</i> , 2014, 4, 896-904.	7.7	88
87	Combination Radiofrequency Ablation with Intratumoral Liposomal Doxorubicin: Effect on Drug Accumulation and Coagulation in Multiple Tissues and Tumor Types in Animals. <i>Radiology</i> , 2005, 235, 469-477.	3.6	84
88	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 808.	5.8	84
89	Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clearâ€cell renal cell carcinoma receiving vascular endothelial growth factorâ€targeted therapy. <i>BJU International</i> , 2010, 106, 772-778.	1.3	81
90	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2174-2184.	3.2	80

#	ARTICLE	IF	CITATIONS
91	Detection of Clonal T-Cell Receptor \hat{I}^3 Gene Rearrangements in Paraffin-Embedded Tissue by Polymerase Chain Reaction and Nonradioactive Single-Strand Conformational Polymorphism Analysis. <i>American Journal of Pathology</i> , 1999, 154, 67-75.	1.9	79
92	Androgen-Driven Prostate Epithelial Cell Proliferation and Differentiation in Vivo Involve the Regulation of p27. <i>Molecular Endocrinology</i> , 2001, 15, 765-782.	3.7	77
93	The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 5218-5226.	3.2	77
94	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. , 2015, 3, 3.		76
95	Combination of Radiofrequency Ablation with Antiangiogenic Therapy for Tumor Ablation Efficacy: Study in Mice. <i>Radiology</i> , 2007, 244, 464-470.	3.6	75
96	Liposomal Doxorubicin Increases Radiofrequency Ablation-induced Tumor Destruction by Increasing Cellular Oxidative and Nitrate Stress and Accelerating Apoptotic Pathways. <i>Radiology</i> , 2010, 255, 62-74.	3.6	75
97	Estrogen Receptor \hat{I}^2 in Prostate Cancer. <i>American Journal of Pathology</i> , 2001, 159, 13-16.	1.9	72
98	p63 in prostate biology and pathology. <i>Journal of Cellular Biochemistry</i> , 2008, 103, 1354-1368.	1.2	72
99	Androgen-Dependent Regulation of Her-2/neu in Prostate Cancer Cells. <i>Cancer Research</i> , 2006, 66, 5723-5728.	0.4	71
100	Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor. <i>Cancer Cell</i> , 2014, 26, 222-234.	7.7	71
101	Obligate Roles for p16 Ink4a and p19 Arf -p53 in the Suppression of Murine Pancreatic Neoplasia. <i>Molecular and Cellular Biology</i> , 2002, 22, 635-643.	1.1	68
102	Perfusion MDCT Enables Early Detection of Therapeutic Response to Antiangiogenic Therapy. <i>American Journal of Roentgenology</i> , 2008, 191, 133-139.	1.0	67
103	Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1925-1934.	3.2	67
104	The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. <i>Genes and Development</i> , 2019, 33, 1718-1738.	2.7	65
105	Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression. <i>PLoS ONE</i> , 2011, 6, e19144.	1.1	64
106	Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. <i>Cancer</i> , 2015, 121, 3435-3443.	2.0	64
107	Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2793-2802.	1.9	63
108	Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 1873-1883.	3.2	63

#	ARTICLE	IF	CITATIONS
109	Reduced Tumor Growth with Combined Radiofrequency Ablation and Radiation Therapy in a Rat Breast Tumor Model. <i>Radiology</i> , 2005, 235, 81-88.	3.6	60
110	The Glomovenous Malformation Protein Glomulin Binds Rbx1 and Regulates Cullin RING Ligase-Mediated Turnover of Fbw7. <i>Molecular Cell</i> , 2012, 46, 67-78.	4.5	59
111	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 555-563.	2.9	59
112	Transition from In Situ to Invasive Testicular Germ Cell Neoplasia is Associated with the Loss of p21 and Gain of mdm-2 Expression. <i>Modern Pathology</i> , 2001, 14, 437-442.	2.9	57
113	A constitutively activated form of the p110 ^β isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 11002-11007.	3.3	57
114	Identification of CDCP1 as a hypoxia-inducible factor 2 [±] (HIF-2 [±]) target gene that is associated with survival in clear cell renal cell carcinoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 3483-3488.	3.3	57
115	KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. <i>Cancer Immunology Research</i> , 2021, 9, 156-169.	1.6	56
116	Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. <i>Oncologist</i> , 2017, 22, 286-292.	1.9	54
117	Melanocytic Nevi of Palms and Soles. <i>American Journal of Surgical Pathology</i> , 1999, 23, 283-287.	2.1	54
118	Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. <i>Lancet Oncology</i> , The, 2013, 14, 81-87.	5.1	52
119	Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo. <i>Molecular Cancer</i> , 2015, 14, 119.	7.9	50
120	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. <i>Clinical Cancer Research</i> , 2019, 25, 6080-6088.	3.2	50
121	Do Liposomal Apoptotic Enhancers Increase Tumor Coagulation and End-Point Survival in Percutaneous Radiofrequency Ablation of Tumors in a Rat Tumor Model?. <i>Radiology</i> , 2010, 257, 685-696.	3.6	49
122	Radiofrequency ablation combined with liposomal quercetin to increase tumour destruction by modulation of heat shock protein production in a small animal model. <i>International Journal of Hyperthermia</i> , 2011, 27, 527-538.	1.1	49
123	Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. <i>Journal of Clinical Oncology</i> , 2018, 36, 3553-3559.	0.8	49
124	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1371-1380.	3.2	49
125	Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5006-5006.	0.8	48
126	Detection of TCR- β gene rearrangements in early mycosis fungoides by non-radioactive PCR-SSCP. <i>Journal of Cutaneous Pathology</i> , 2000, 27, 228-234.	0.7	47

#	ARTICLE	IF	CITATIONS
127	Primary effusion lymphoma in HIV-infected patients with multicentric Castleman's disease. <i>Journal of Pathology</i> , 2001, 193, 200-209.	2.1	47
128	Improved Tumor Destruction with Arsenic Trioxide and Radiofrequency Ablation in Three Animal Models. <i>Radiology</i> , 2006, 240, 82-89.	3.6	47
129	Opposing Effects of Androgen Deprivation and Targeted Therapy on Prostate Cancer Prevention. <i>Cancer Discovery</i> , 2013, 3, 44-51.	7.7	47
130	HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species. <i>Science Signaling</i> , 2019, 12, .	1.6	47
131	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. <i>Cancer Immunology Research</i> , 2020, 8, 1075-1084.	1.6	47
132	Collecting duct carcinoma of the kidney is associated with <i>CDKN2A</i> deletion and <i>SLC</i> family gene up-regulation. <i>Oncotarget</i> , 2016, 7, 29901-29915.	0.8	47
133	Correlation of Apobec Mrna Expression with overall Survival and pd-1 Expression in Urothelial Carcinoma. <i>Scientific Reports</i> , 2016, 6, 27702.	1.6	46
134	Tumor Vascularity in Renal Masses: Correlation of Arterial Spin-Labeled and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Assessments. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e25-e36.	0.9	44
135	Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN [±] mice by the p85 regulatory subunits of phosphoinositide 3-kinase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 10238-10243.	3.3	43
136	Defining Cell Lineages in the Prostate Epithelium. <i>Cell Cycle</i> , 2006, 5, 138-141.	1.3	42
137	Risk of Bilateral Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3737-3741.	0.8	42
138	Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1788-1793.	0.8	41
139	Integrative clinical and molecular characterization of translocation renal cell carcinoma. <i>Cell Reports</i> , 2022, 38, 110190.	2.9	40
140	Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). <i>Journal of Clinical Oncology</i> , 2022, 40, 2913-2923.	0.8	40
141	GRK3 is essential for metastatic cells and promotes prostate tumor progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 1521-1526.	3.3	39
142	RNA-seq Reveals Aurora Kinase-Driven mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. <i>Molecular Cancer Research</i> , 2015, 13, 130-137.	1.5	38
143	Tissue biomarkers in renal cell carcinoma: Issues and solutions. <i>Cancer</i> , 2009, 115, 2290-2297.	2.0	36
144	Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 820-824.	2.3	36

#	ARTICLE	IF	CITATIONS
145	HIF activation causes synthetic lethality between the <i>VHL</i> tumor suppressor and the <i>EZH1</i> histone methyltransferase. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	36
146	Prostate stem cells: From development to cancer. <i>Seminars in Cancer Biology</i> , 2007, 17, 219-224.	4.3	35
147	Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. <i>Journal of Pathology</i> , 2011, 225, 212-221.	2.1	35
148	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. <i>Future Oncology</i> , 2019, 15, 1683-1695.	1.1	35
149	Adult Renal Cell Carcinoma. <i>Surgical Pathology Clinics</i> , 2015, 8, 587-621.	0.7	33
150	Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 118, 1238-1242.	2.9	33
151	Treatment selection for patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2009, 115, 2327-2333.	2.0	32
152	Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2868-2878.	3.2	32
153	Intratumor Heterogeneity of Perfusion and Diffusion in Clear-Cell Renal Cell Carcinoma: Correlation With Tumor Cellularity. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e585-e594.	0.9	31
154	Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. <i>Journal of Urology</i> , 2017, 198, 817-823.	0.2	31
155	Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2 α . <i>European Journal of Cancer</i> , 2014, 50, 1531-1540.	1.3	29
156	ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	29
157	p63 Promotes Cell Survival through Fatty Acid Synthase. <i>PLoS ONE</i> , 2009, 4, e5877.	1.1	29
158	D-Cyclins Repress Apoptosis in Hematopoietic Cells by Controlling Death Receptor Fas and Its Ligand FasL. <i>Developmental Cell</i> , 2014, 30, 255-267.	3.1	27
159	Cytokeratin15-Positive Basal Epithelial Cells Targeted in Graft-Versus-Host Disease Express a Constitutive Antiapoptotic Phenotype. <i>Journal of Investigative Dermatology</i> , 2007, 127, 106-115.	0.3	26
160	Tissue-Based Research in Kidney Cancer: Current Challenges and Future Directions. <i>Clinical Cancer Research</i> , 2008, 14, 3699-3705.	3.2	24
161	Suppression of <i>CHK1</i> by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. <i>Cancer Discovery</i> , 2015, 5, 550-563.	7.7	24
162	Immunohistochemical staining for BRAF V600E supports the diagnosis of metanephric adenoma. <i>Histopathology</i> , 2015, 66, 901-904.	1.6	23

#	ARTICLE	IF	CITATIONS
163	Gene Transcript Quantitation by Real-Time RT-PCR in Cells Selected by Immunohistochemistry-Laser Capture Microdissection. <i>Diagnostic Molecular Pathology</i> , 2002, 11, 187-192.	2.1	22
164	Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. , 2020, 8, e001467.		22
165	Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 548-548.	0.8	21
166	Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. <i>Oncotarget</i> , 0, 7, 41857-41869.	0.8	21
167	MET as a Target in Papillary Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 3361-3363.	3.2	20
168	A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. <i>Clinical Cancer Research</i> , 2021, 27, 4836-4847.	3.2	20
169	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. <i>Oncotarget</i> , 2017, 8, 103428-103436.	0.8	19
170	Hypoxia regulation of the cell cycle in malignant melanoma: putative role for the cyclin-dependent kinase inhibitor p27Kip1. <i>Journal of Cutaneous Pathology</i> , 2004, 31, 477-482.	0.7	18
171	Pml represses tumour progression through inhibition of mTOR. <i>EMBO Molecular Medicine</i> , 2011, 3, 249-257.	3.3	18
172	Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer. <i>Cancer Research</i> , 2022, 82, 248-263.	0.4	17
173	A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. <i>Cancer</i> , 2016, 122, 2389-2398.	2.0	16
174	Anti-CAIX BBÎ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 385-399.	2.0	15
175	RET protein expression in papillary renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 900-905.	0.8	14
176	Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. <i>PLoS Genetics</i> , 2018, 14, e1007679.	1.5	14
177	Loss of <i>LDAH</i> associated with prostate cancer and hearing loss. <i>Human Molecular Genetics</i> , 2018, 27, 4194-4203.	1.4	14
178	p63+ ureteric bud tip cells are progenitors of intercalated cells. <i>JCI Insight</i> , 2017, 2, .	2.3	14
179	ÎNp63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity. <i>Human Pathology</i> , 2015, 46, 384-389.	1.1	13
180	Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy. <i>BJU International</i> , 2008, 101, 31-35.	1.3	12

#	ARTICLE	IF	CITATIONS
181	Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. <i>European Urology Focus</i> , 2016, 2, 633-639.	1.6	12
182	FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 2159-2168.	3.2	12
183	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. <i>Clinical Cancer Research</i> , 2022, 28, 831-839.	3.2	12
184	Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3633-3641.	0.8	12
185	Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 4045-4055.	3.2	12
186	Young investigator challenge: Application of cytologic techniques to circulating tumor cell specimens: Detecting activation of the oncogenic transcription factor <scp>STAT3</scp>. <i>Cancer Cytopathology</i> , 2015, 123, 696-706.	1.4	11
187	Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 304-313.e6.	0.9	11
188	Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 690-696.	1.9	11
189	Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (NccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (ccRCCsd): Updated results of activity and predictive biomarkers from a phase II study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4583-4583.	0.8	11
190	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS684-TPS684.	0.8	11
191	Sensitivity of <i>VHL</i> mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2120403119.	3.3	11
192	Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3741-E3748.	3.3	10
193	Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. <i>BMC Cancer</i> , 2021, 21, 904.	1.1	10
194	Identification of ALK Gene Alterations in Urothelial Carcinoma. <i>PLoS ONE</i> , 2014, 9, e103325.	1.1	9
195	Integrated genomic correlates of response to PD-1 inhibitor nivolumab in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 545-545.	0.8	9
196	Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8⁺ T cells on clinical benefit from PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 477-477.	0.8	9
197	Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5024-5024.	0.8	9
198	Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. <i>Clinical Cancer Research</i> , 2022, 28, 748-755.	3.2	9

#	ARTICLE	IF	CITATIONS
199	Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.. Journal of Clinical Oncology, 2022, 40, 352-352.	0.8	8
200	Renal-cell carcinoma: a step closer to a new classification. Lancet Oncology, The, 2013, 14, 105-107.	5.1	7
201	Cell Kinetic Studies Fail to Identify Sequentially Proliferating Progenitors as the Major Source of Epithelial Renewal in the Adult Murine Prostate. PLoS ONE, 2015, 10, e0128489.	1.1	7
202	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. Journal of Clinical Oncology, 2017, 35, TPS4596-TPS4596.	0.8	7
203	Blood Levels of Carbonic Anhydrase 9 Correlate with Clear Cell Renal Cell Carcinoma Activity. Clinical Proteomics, 2009, 5, 37-45.	1.1	6
204	Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.. Journal of Clinical Oncology, 2020, 38, 5023-5023.	0.8	6
205	Blocking PI3K p110 β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. Molecular Cancer Research, 2022, 20, 673-685.	1.5	6
206	Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report.. Journal of Clinical Oncology, 2022, 40, 288-288.	0.8	6
207	Transgenic Expression of Polyomavirus Middle T Antigen in the Mouse Prostate Gives Rise to Carcinoma. Journal of Virology, 2011, 85, 5581-5592.	1.5	5
208	Killer immunoglobulin-like receptor (KIR) and KIR*ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. Cancer Immunology, Immunotherapy, 2016, 65, 1523-1532.	2.0	5
209	Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2018, 16, 341-348.	0.9	5
210	PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. Journal of Clinical Oncology, 2021, 39, TPS4596-TPS4596.	0.8	5
211	Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs).. Journal of Clinical Oncology, 2019, 37, 103-103.	0.8	5
212	Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2019, 37, 4514-4514.	0.8	5
213	SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC).. Journal of Clinical Oncology, 2020, 38, 5002-5002.	0.8	5
214	<i>BRCA1/Trp53</i> heterozygosity and replication stress drive esophageal cancer development in a mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	5
215	Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. JCO Precision Oncology, 2022, 6, e2100448.	1.5	5
216	Primary effusion lymphoma in HIV*infected patients with multicentric Castleman's disease. Journal of Pathology, 2001, 193, 200-209.	2.1	4

#	ARTICLE	IF	CITATIONS
217	Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).. Journal of Clinical Oncology, 2019, 37, 4568-4568.	0.8	4
218	MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data.. Journal of Clinical Oncology, 2020, 38, e19321-e19321.	0.8	4
219	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. Journal of Clinical Oncology, 2019, 37, TPS4597-TPS4597.	0.8	3
220	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2020, 38, 715-715.	0.8	3
221	PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. Journal of Clinical Oncology, 2020, 38, TPS5101-TPS5101.	0.8	3
222	Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience.. Journal of Clinical Oncology, 2022, 40, 4531-4531.	0.8	3
223	Abstract 62: Development of dual-targeted fine-tuned immune restoring (DFIR) CAR T cell therapy for clear cell renal cell carcinoma (ccRCC). Cancer Research, 2021, 81, 62-62.	0.4	2
224	The impact of BMI on outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy: An external validation data set and analysis of underlying biology from The Cancer Genome Atlas.. Journal of Clinical Oncology, 2015, 33, 405-405.	0.8	2
225	A phase II trial of sunitinib and gemcitabine in sarcomatoid and/or poor-risk patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 408-408.	0.8	2
226	Evaluation of predictive biomarkers for nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) using RECIST and immune-related (IR) RECIST.. Journal of Clinical Oncology, 2018, 36, 619-619.	0.8	2
227	Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.. Journal of Clinical Oncology, 2020, 38, 5010-5010.	0.8	2
228	Evolution of circulating tumor DNA (ctDNA) profile from first-line (1L) to second-line (2L) therapy in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2017, 35, 434-434.	0.8	2
229	Metastatic penile carcinoma associated with convergent gain-of-function mutations in NOTCH1. Human Pathology: Case Reports, 2018, 11, 19-20.	0.2	1
230	Inhibition of tumor growth in a VEGFR TKI-resistant model of renal cell carcinoma using dalantercept combined with sunitinib.. Journal of Clinical Oncology, 2013, 31, 370-370.	0.8	1
231	Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort.. Journal of Clinical Oncology, 2015, 33, 4519-4519.	0.8	1
232	Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2015, 33, 422-422.	0.8	1
233	Association of higher PD-L1 expression in tumor cells of metastatic ccRCC lesions with worse overall survival.. Journal of Clinical Oncology, 2016, 34, e23221-e23221.	0.8	1
234	Programmed death-ligand 1 (PD-L1) expression in cured and not cured testicular and other germ cell tumors (GCT).. Journal of Clinical Oncology, 2016, 34, 485-485.	0.8	1

#	ARTICLE	IF	CITATIONS
235	T-cell receptor (TCR) repertoire in metastatic renal cell carcinoma (RCC) patients treated with first-line vascular endothelial growth factor receptor blockade.. Journal of Clinical Oncology, 2016, 34, 501-501.	0.8	1
236	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression.. Journal of Clinical Oncology, 2017, 35, 4573-4573.	0.8	1
237	Genomic profiling of nephrectomy and metastatic sites in patients with advanced clear cell renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2017, 35, 513-513.	0.8	1
238	Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, 626-626.	0.8	1
239	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. Journal of Clinical Oncology, 2018, 36, TPS710-TPS710.	0.8	1
240	PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. Journal of Clinical Oncology, 2020, 38, TPS765-TPS765.	0.8	1
241	Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial.. Journal of Clinical Oncology, 2020, 38, 740-740.	0.8	1
242	In Reply. Oncologist, 2017, 22, 1561-1561.	1.9	0
243	Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BE2235 Compared with Rapamycin in Renal Cell Carcinoma. Clinical Cancer Research, 2019, 25, 4194-4194.	3.2	0
244	Adult Prostate Epithelium Renewal, Stem Cells and Cancer. , 2009, , 231-246.		0
245	Tissue Biomarkers in Renal Cell Carcinoma: Intermediate Endpoints in the Selection of Targeted Agents for RCC. , 2012, , 69-89.		0
246	Relationship of ERCC1 genotype variant with mRNA expression and ERCC1 protein levels in advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2013, 31, 260-260.	0.8	0
247	A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates.. Journal of Clinical Oncology, 2013, 31, 278-278.	0.8	0
248	Investigating the association of cytoplasmic and nuclear HIF-2 expression with cancer specific survival (CSS) in clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 387-387.	0.8	0
249	Prognostic value of genomic signatures in metastatic Clear Cell Renal Cell Carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data.. Journal of Clinical Oncology, 2015, 33, 4560-4560.	0.8	0
250	The impact of PBRM1 and BAP1 expression on outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. Journal of Clinical Oncology, 2016, 34, 616-616.	0.8	0
251	Differential expression of PD-L1 expression in high grade T1 (HGT1) v. muscle invasive urothelial carcinoma (MIUC) and its prognostic implications.. Journal of Clinical Oncology, 2016, 34, 4535-4535.	0.8	0
252	The association of tumor infiltrating CD8+ and Foxp3+ cells with overall response rate (ORR) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose aldesleukin (HD IL-2).. Journal of Clinical Oncology, 2017, 35, 4576-4576.	0.8	0

#	ARTICLE	IF	CITATIONS
253	Statin use and risk of renal cell carcinoma in three prospective cohort studies.. Journal of Clinical Oncology, 2018, 36, 679-679.	0.8	0
254	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. Journal of Clinical Oncology, 2018, 36, TPS4597-TPS4597.	0.8	0
255	Prognostic significance of CD73 expression in localized renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2019, 37, 4582-4582.	0.8	0
256	Evaluation of RNA-sequencing (RNA-seq) signatures with pembrolizumab (pembro) in patients (pts) with renal cell carcinoma (RCC) from KEYNOTE-427 cohort A.. Journal of Clinical Oncology, 2020, 38, 729-729.	0.8	0
257	Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation.. Journal of Clinical Oncology, 2022, 40, 569-569.	0.8	0
258	Molecular characterization of the tumor microenvironment in chromophobe renal cell carcinoma (ChRCC) and related oncocytic neoplasms.. Journal of Clinical Oncology, 2022, 40, 4549-4549.	0.8	0